For those at risk for Type 1 allergic reactions, the World can be a very scary place. Since the early 1990s, intramuscular injectables have been the only solutions for immediate epinephrine delivery…UNTIL NOW!
Introducing Nasdepi®
The first dry powder nasal device for treatment of anaphylaxis.
Nasdepi® is Belhaven’s lead program for the treatment of life-threatening allergic reactions (anaphylaxis).
Many people with severe allergies either do not have immediate access to treatment or fail to use treatment due to the expense, availability, and hesitancy to use epinephrine autoinjectors. Nasdepi® will provide patients and healthcare providers with an alternative over a decades old treatment.
How Nasdepi®Relieves the Pain Points of Injectable Epinephrine
Any Type 1 allergic reaction can lead to anaphylaxis and patients can be hesitant to use the currently available rescue medication. The risk of death among those who suffer a reaction has been estimated to be about 1%, with as many as 500 to 1000 deaths annually. Despite these statistics, fewer than half of those at risk in the U.S. carry injectable epinephrine pens. Why?
Injectable Epinephrine
- Fear of needles
- Expensive
- Complicated device
- Awkward to carry with you
Nasdepi®
- A proprietary intranasal formulation
- Superior epinephrine absorption
- Simple to use
- Long shelf life
- Fits easily in a pocket
